MedTrace Logo

Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously

NCT00788294 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2020-10-06

No results posted yet for this study

Summary

The hypothesis of this study is that subcutaneous administration of tanezumab results in lower drug exposure compared to intravenous administration of tanezumab.

Conditions

  • Healthy Volunteers

Interventions

BIOLOGICAL

tanezumab

Drug solution given intravenously only once at dose of 10 mg

BIOLOGICAL

tanezumab

Drug solution given subcutaneously only once at dose of 5 mg.

BIOLOGICAL

tanezumab

Drug solution given subcutaneously only once at dose of 10 mg.

BIOLOGICAL

tanezumab

Drug solution given subcutaneously only once at dose of 19 mg.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2009-06-30
Completion
2009-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00788294 on ClinicalTrials.gov